The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …
The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
New blood biomarker data from Eli Lilly, Roche and Alamar Biosciences headline a London conference where non-amyloid mechanisms …
The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase …
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII replacement …
Genmab and AbbVie’s bispecific antibody met its primary endpoint in a head-to-head comparison, positioning the CD3xCD20 therapy for …
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
Already a subscriber? Log in